📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
56 announcements match the current filters (relevance ≥ 5).
Anlon Healthcare to Quadruple Capacity to 1,600 MTPA via Acquisitions; Targets 30% Revenue CAGR
Anlon Healthcare is aggressively scaling its operations through the strategic acquisitions of Bizotic Lifescience and Apiqo Organics, aiming to increase total manufacturing capacity from 400 MTPA to 1,600 MTPA by FY26. The company has provided a growth guidance of 30% revenue CAGR over the next three years, supported by 21 global DMF filings and a significant shift in revenue mix toward pharmaceutical intermediates (71.8% in 9M FY26). Furthermore, the company is diversifying into high-growth sectors including e-waste management and lithium-ion battery recycling to drive long-term value.
Key Highlights
Total production capacity projected to reach 1,400-1,600 MTPA by FY26, a 4x increase from the current 400 MTPA.
Acquired 56.67% stake in Bizotic Lifescience for ₹3.79 crore and 67.48% in Apiqo Organics for ₹5.40 crore.
Management targets a 30% revenue CAGR over the next 3 years backed by a pipeline of 65 commercialized products.
Pharmaceutical Intermediates revenue contribution surged to 71.81% in 9M FY26 compared to 24.60% in 9M FY25.
Global regulatory footprint strengthened with 21 DMF filings and approvals from EDQM (Europe), ANVISA (Brazil), and NMPA (China).
👀 What to Watch
Investors should monitor the successful integration of the two new acquisitions and the execution of the 30% CAGR growth guidance. The massive capacity expansion and entry into battery recycling offer significant upside potential, though operational efficiency during this rapid scaling phase will be key.
Anlon Healthcare Q3 FY26 PAT Turns Positive at ₹5.15 Cr; EBITDA Surges 20x YoY
Anlon Healthcare reported a massive turnaround in Q3 FY26, with total income growing 281% YoY to ₹35.78 crore. The company's EBITDA skyrocketed by over 2,000% to ₹12.54 crore, while PAT turned positive at ₹5.15 crore compared to a loss in the previous year. For the nine-month period, PAT grew by 365% to ₹18.02 crore with margins expanding significantly by 943 bps. Additionally, the company completed the acquisition of Apiqo Organics and is acquiring Bizotic Lifescience to boost capacity to 1,600 MTPA.
Key Highlights
Q3 FY26 Total Income surged 281.47% YoY to ₹35.78 crore.
EBITDA for Q3 grew 20x to ₹12.54 crore with PAT turning positive at ₹5.15 crore.
9M FY26 PAT increased by 365.61% YoY to ₹18.02 crore with a 14.85% margin.
Acquired 67.48% stake in Apiqo Organics for ₹5.40 crore to strengthen backward integration.
Management targets a 30% revenue CAGR over the next three years with capacity expansion to 1,600 MTPA.
👀 What to Watch
Investors should view this as a strong growth signal given the massive margin expansion and strategic acquisitions. Monitor the integration of new subsidiaries and the achievement of the 30% CAGR guidance.
Anlon Healthcare Q3 PAT Drops 44.7% to ₹5.15 Cr; Appoints New CFO and Director
Anlon Healthcare Limited reported a significant decline in its Q3 FY26 performance, with revenue from operations falling 50.1% year-on-year to ₹35.58 crore. Net profit for the quarter also dropped sharply to ₹5.15 crore from ₹9.32 crore in the same period last year. However, on a nine-month basis, the company's profit after tax showed a substantial increase to ₹18.02 crore compared to ₹3.87 crore in the previous year. Alongside the results, the company announced the appointment of Mr. Naimish Dilipbhai Bhatt as the new CFO and Mr. Kishan Vinodkumar Raja as an Independent Director.
Key Highlights
Revenue from operations for Q3 FY26 fell 50.1% YoY to ₹35.58 crore from ₹71.36 crore.
Net profit for the quarter decreased by 44.7% YoY to ₹5.15 crore.
9M FY26 profit after tax stands at ₹18.02 crore, a significant jump from ₹3.87 crore in 9M FY25.
Mr. Naimish Dilipbhai Bhatt appointed as CFO effective February 09, 2026, succeeding Mr. Hitesh Makwana.
CA Kishan Vinodkumar Raja appointed as an Independent Director to strengthen board-level oversight.
👀 What to Watch
Investors should monitor the reasons behind the sharp quarterly revenue and profit contraction despite the overall 9M growth. The leadership transition in the finance department warrants a watchful approach to see if operational efficiencies improve in the coming quarters.
Anlon Healthcare Q3 PAT Drops to ₹5.15 Cr; Announces CFO and Board Transitions
Anlon Healthcare Limited reported a sequential decline in its financial performance for the quarter ended December 31, 2025, with revenue from operations falling to ₹35.58 crore from ₹52.20 crore in the previous quarter. Net profit also saw a significant drop to ₹5.15 crore compared to ₹9.32 crore in Q2 FY26. Alongside the earnings, the company announced the resignation of CFO Hitesh Bhavanjibhai Makwana, who is replaced by Naimish Dilipbhai Bhatt. The board also saw the appointment of a new Independent Director, Kishan Vinodkumar Raja, following the resignation of Shailesh Kantilal Thakkar due to health reasons.
Key Highlights
Revenue from operations decreased by 31.8% sequentially to ₹35.58 crore in Q3 FY26.
Net Profit (PAT) for the quarter stood at ₹5.15 crore, down from ₹9.32 crore in the preceding quarter.
Total income for the nine-month period ended December 31, 2025, reached ₹121.32 crore with a PAT of ₹18.02 crore.
Appointment of Naimish Dilipbhai Bhatt as the new CFO, effective February 09, 2026.
Board reshuffle with the appointment of CA Kishan Vinodkumar Raja as an Independent Director.
👀 What to Watch
Investors should exercise caution due to the sharp sequential decline in both top-line and bottom-line performance. Monitor the new CFO's ability to manage costs and stabilize margins in the upcoming quarters.
Anlon Healthcare Q3 PAT Falls 45% YoY to ₹5.15 Cr; Appoints New CFO and Director
Anlon Healthcare reported a weak third quarter for FY26, with revenue from operations dropping 50% YoY to ₹35.58 crore. Quarterly Net Profit (PAT) also saw a significant decline of 44.7% YoY, falling to ₹5.15 crore. However, the nine-month (9M) performance remains robust, with PAT surging to ₹18.02 crore compared to ₹3.87 crore in the previous year. Alongside results, the company announced a management overhaul, including the appointment of a new CFO and an Independent Director following resignations.
Key Highlights
Q3 Revenue from operations declined 50.1% YoY to ₹35.58 crore from ₹71.36 crore.
Net Profit (PAT) for the quarter fell 44.7% YoY to ₹5.15 crore compared to ₹9.32 crore in the previous year.
9M FY26 PAT shows a massive growth of 365% YoY, reaching ₹18.02 crore.
Appointment of Naimish Dilipbhai Bhatt as CFO, replacing Hitesh Bavanjibhai Makwana.
Kishan Vinodkumar Raja appointed as Independent Director following the resignation of Shailesh Kantilal Thakkar.
👀 What to Watch
Investors should investigate the cause of the sharp Q3 revenue and profit contraction despite the strong 9M performance. The management transition in the finance department should be monitored for any impact on internal controls or strategic direction.
Anlon Healthcare Q3 FY26 Revenue Drops 50% YoY; New CFO Appointed
Anlon Healthcare reported a sharp decline in its Q3 FY26 performance, with revenue from operations falling 50% YoY to ₹35.58 crore. Net profit for the quarter also decreased significantly to ₹5.15 crore from ₹9.32 crore in the corresponding quarter last year. However, on a 9-month basis, the company showed resilience with a net profit of ₹18.02 crore compared to just ₹3.87 crore in the previous year. The company also announced a management shuffle, appointing Mr. Naimish Dilipbhai Bhatt as the new CFO.
Key Highlights
Quarterly revenue from operations fell 50.1% YoY to ₹35.58 crore in Q3 FY26
Net profit for the quarter declined 44.7% YoY to ₹5.15 crore
9-month cumulative net profit rose significantly to ₹18.02 crore from ₹3.87 crore YoY
Appointment of Mr. Naimish Dilipbhai Bhatt as CFO effective February 09, 2026
Mr. Kishan Vinodkumar Raja appointed as an Additional Non-Executive Independent Director
👀 What to Watch
Investors should investigate the cause of the sharp 50% quarterly revenue drop despite the strong 9-month profit growth. Monitor the impact of the new CFO on financial reporting and internal controls in the coming quarters.
Anlon Healthcare Q3 PAT Hits ₹5.15 Cr Amid 50% Revenue Drop; New CFO Appointed
Anlon Healthcare reported a significant decline in Q3 FY26 revenue, which fell to ₹35.58 crore from ₹71.36 crore in the same period last year. Despite the top-line contraction, the company achieved a turnaround in profitability, posting a net profit of ₹5.15 crore compared to a loss of ₹2.49 crore in Q3 FY25. For the nine-month period ending December 2025, PAT surged to ₹18.02 crore from ₹3.87 crore year-on-year. The company also announced a management shuffle, appointing Mr. Naimish Dilipbhai Bhatt as the new CFO following the resignation of Mr. Hitesh Bavanjibhai Makwana.
Key Highlights
Revenue from operations for Q3 FY26 declined 50% YoY to ₹35.58 crore from ₹71.36 crore.
Net Profit (PAT) for the quarter stood at ₹5.15 crore, recovering from a net loss of ₹2.49 crore in Q3 FY25.
9-month PAT showed robust growth, reaching ₹18.02 crore compared to ₹3.87 crore in the previous year.
Mr. Naimish Dilipbhai Bhatt appointed as CFO, bringing over 18 years of experience in financial reporting and compliance.
Board changes include the appointment of CA Kishan Vinodkumar Raja as an Independent Director and the resignation of Mr. Shailesh Kantilal Thakkar.
👀 What to Watch
Investors should closely monitor the reasons behind the sharp 50% decline in quarterly revenue despite the improved profit margins. The transition in the CFO role and board composition requires observation to ensure operational stability and a return to top-line growth.
Anlon Healthcare Q3 PAT at ₹5.15 Cr; Appoints New CFO and Independent Director
Anlon Healthcare reported a standalone Profit After Tax (PAT) of ₹5.15 crore for the quarter ended December 31, 2025, a significant recovery from a loss of ₹2.48 crore in the same period last year. However, revenue from operations saw a sharp decline of 50% year-on-year, falling to ₹35.57 crore from ₹71.35 crore. For the nine-month period, the company showed robust performance with PAT surging to ₹18.01 crore compared to ₹3.87 crore in the previous year. The company also announced a management transition, appointing Mr. Naimish Dilipbhai Bhatt as the new CFO following the resignation of Mr. Hitesh Makwana.
Key Highlights
Q3 FY26 PAT stood at ₹5.15 crore, turning around from a loss of ₹2.48 crore in Q3 FY25.
Revenue from operations for the quarter dropped 50% YoY to ₹35.57 crore.
9M FY26 PAT increased significantly to ₹18.01 crore from ₹3.87 crore in 9M FY25.
Total expenses for Q3 FY26 were drastically reduced to ₹25.16 crore from ₹71.28 crore in the year-ago quarter.
Management changes include a new CFO and the appointment of Mr. Kishan Vinodkumar Raja as an Independent Director.
👀 What to Watch
Investors should investigate the cause of the 50% drop in quarterly revenue despite the improved profitability. Monitor the impact of the new CFO on financial reporting and internal controls.
Anlon Healthcare Q3 Revenue Drops 50% YoY; 9M PAT Surges to ₹18.02 Cr
Anlon Healthcare Limited reported a significant decline in its quarterly performance for Q3 FY26, with revenue from operations falling 50% YoY to ₹35.58 crore. Despite the quarterly slump, the nine-month (9M) performance shows a massive surge in Profit After Tax (PAT) to ₹18.02 crore, up from ₹3.87 crore in the previous year, largely due to better cost management over the full period. The company also announced a leadership transition, appointing Naimish Dilipbhai Bhatt as the new CFO and Kishan Vinodkumar Raja as an Independent Director. The sharp quarterly revenue contraction remains a point of concern for short-term growth momentum.
Key Highlights
Q3 FY26 Revenue from operations fell 50.1% YoY to ₹35.58 crore from ₹71.36 crore.
Quarterly Net Profit (PAT) declined to ₹5.15 crore in Q3 FY26 compared to ₹9.32 crore in Q3 FY25.
9M FY26 PAT increased significantly to ₹18.02 crore from ₹3.87 crore in the corresponding nine-month period last year.
Naimish Dilipbhai Bhatt appointed as Chief Financial Officer (CFO) effective February 09, 2026.
Kishan Vinodkumar Raja, a Chartered Accountant with 14 years of experience, appointed as an Independent Director.
👀 What to Watch
Investors should seek clarity on why Q3 revenues halved despite the strong cumulative 9M profit growth. The management transition in the finance department should be monitored to ensure continued stability in financial reporting.
Anlon Healthcare Q3 PAT Drops 44.7% YoY to ₹5.15 Cr; CFO and Board Changes Announced
Anlon Healthcare reported a weak performance for the quarter ended December 31, 2025, with revenue from operations falling 50% year-on-year to ₹35.58 crore. Net profit for the quarter also saw a significant decline of 44.7%, reaching ₹5.15 crore compared to ₹9.32 crore in the same period last year. While nine-month revenue showed growth at ₹121.08 crore, the overall profitability for the nine-month period remains lower than the previous year. The company also announced a transition in leadership with the appointment of Mr. Naimish Dilipbhai Bhatt as the new CFO.
Key Highlights
Revenue from operations for Q3 FY26 fell 50.1% YoY to ₹35.58 crore from ₹71.36 crore.
Net Profit for the quarter declined 44.7% YoY to ₹5.15 crore against ₹9.32 crore in Q3 FY25.
9-month revenue for FY26 grew to ₹121.08 crore compared to ₹93.57 crore in the previous year.
Mr. Naimish Dilipbhai Bhatt appointed as CFO following the resignation of Mr. Hitesh Bavanjibhai Makwana.
Mr. Kishan Vinodkumar Raja appointed as an Independent Director, while Mr. Shailesh Kantilal Thakkar resigned due to health reasons.
👀 What to Watch
Investors should exercise caution given the sharp quarterly contraction in both revenue and profit. It is important to monitor whether the new CFO can address the volatility in financial performance and improve margins in upcoming quarters.
Anlon Healthcare Commences Exports to Italy and Germany Following India-EU Trade Pact
Anlon Healthcare Limited (AHCL) has announced the commencement of exports for one of its key products to Italy and Germany. This strategic move follows the signing of a trade agreement between the Government of India and the European Union (EU) to enhance bilateral trade. The company expects this expansion into high-value regulated markets to have a positive impact on its operational performance. This development validates the company's product quality standards for the European market.
Key Highlights
Successful export of a key product to Italy and Germany within the European Union
Strategic alignment with the newly signed India-EU trade agreement
Anticipated positive impact on company operations and international revenue streams
Entry into highly regulated European markets which typically offer higher margins
👀 What to Watch
Investors should monitor the revenue contribution from these new EU markets in upcoming quarterly reports. The ability to export to Italy and Germany is a positive indicator of the company's compliance with international quality standards.
Anlon Healthcare Completes Acquisition of 67.48% Stake in Apiqo Organics
Anlon Healthcare Limited (AHCL) has officially completed the acquisition of a 67.48% equity stake in Apiqo Organics Private Limited as of January 9, 2026. This transaction follows the Share Purchase Agreement executed on December 2, 2025, and marks the successful transition of the target company into a subsidiary. Apiqo Organics, formerly known as Apple Life Science, will now be consolidated into AHCL's financial statements. This strategic move is intended to expand the company's operational footprint and market presence.
Key Highlights
Successfully acquired 67.48% equity shareholding in Apiqo Organics Private Limited
Apiqo Organics has officially become a subsidiary of Anlon Healthcare Limited
The acquisition was finalized on January 9, 2026, following the SPA dated December 2, 2025
Target company was previously a partnership firm operating under the name M/s Apple Life Science
👀 What to Watch
Investors should monitor the upcoming quarterly results to assess the revenue and margin contribution from the newly acquired subsidiary. This acquisition indicates a growth-oriented strategy that could enhance long-term shareholder value.
Anlon Healthcare Shareholders Approve Variation in IPO Objects for Inorganic Growth
Anlon Healthcare Limited (AHCL) has received overwhelming shareholder approval to modify the utilization of its Initial Public Offering (IPO) proceeds. The special resolution, passed with 99.99% of the votes in favor, allows the company to redirect funds toward proposed expansion through inorganic growth and further facility upgradation. A total of 30.45 million votes were cast, representing approximately 57.29% of the total paid-up equity capital. This strategic shift indicates management's intent to pursue acquisitions or partnerships to accelerate business scaling.
Key Highlights
Special resolution passed with 99.99% majority (30,448,093 votes in favor vs 46 against)
Total voter turnout recorded at 57.29% of the total paid-up equity capital of 53,151,500 shares
IPO proceeds redirected toward inorganic growth opportunities and facility upgradation
The remote e-voting process concluded on January 07, 2026, with 11,732 shareholders on record
The change in capital allocation was supported by 100% of the promoter group votes polled
👀 What to Watch
Investors should monitor the company's future announcements regarding potential acquisitions or partnerships, as this change signals an aggressive inorganic growth strategy. The high level of shareholder consensus reflects strong confidence in management's revised capital allocation plan.
Anlon Healthcare to Vary IPO Objects for Inorganic Growth via Postal Ballot
Anlon Healthcare Limited (AHCL) has issued a postal ballot notice seeking shareholder approval to modify the utilization of its IPO proceeds. The company proposes to redirect funds originally earmarked for specific capital expenditures, as per its August 30, 2025 prospectus, toward inorganic growth opportunities and further facility upgradation. Shareholders can cast their votes electronically until January 07, 2026, with the final results expected by January 09, 2026. This strategic shift suggests the company is looking to accelerate expansion through acquisitions shortly after its public listing.
Key Highlights
Proposed Special Resolution to vary the objects of the IPO proceeds from the August 30, 2025 prospectus.
Funds to be redirected toward inorganic growth (acquisitions) and further facility upgradation.
Remote e-voting period is open until January 07, 2026, at 5:00 p.m. IST.
The company has appointed Mr. Keyur Ghelani as the Scrutinizer for the voting process.
Results of the postal ballot will be announced on or before Friday, January 09, 2026.
👀 What to Watch
Investors should monitor the company's specific plans for inorganic growth to ensure capital is being deployed into value-accretive acquisitions. A shift in strategy so soon after an IPO requires careful observation of management's execution and the quality of potential targets.
Anlon Healthcare to Develop New Products and Acquire Two Entities; Seeks IPO Object Variation
Anlon Healthcare Limited has approved the development of two new products, Butamirate Citrate and Ketoprofen Lysinate, along with capacity enhancement to strengthen its market position. The Board also discussed the strategic acquisition of two entities as subsidiaries to drive inorganic growth. To facilitate these plans, the company is seeking shareholder approval via postal ballot to vary the utilization of its IPO proceeds. The e-voting period for this resolution is scheduled from December 09, 2025, to January 07, 2026.
Key Highlights
Approved the initiation of new product development for Butamirate Citrate and Ketoprofen Lysinate.
Proposed the acquisition of two entities to be integrated as subsidiaries for inorganic expansion.
Approved variation in IPO objects to reallocate funds for expansion and upgradation.
Fixed December 05, 2025, as the cut-off date for the postal ballot and remote e-voting process.
Remote e-voting period set to run from December 09, 2025, to January 07, 2026.
👀 What to Watch
Investors should monitor the specific details and valuations of the two proposed acquisitions as they are finalized. The shift in IPO object utilization suggests a pivot toward inorganic growth which could accelerate revenue but requires careful execution.
AHCL acquires 67.48% stake in Apiqo Organics for ₹5,40,06,960
Anlon Healthcare Limited (AHCL) has entered into a Share Purchase Agreement (SPA) to acquire a 67.48% shareholding in Apiqo Organics Private Limited. The acquisition cost is ₹5,40,06,960 for 55,33,500 equity shares priced at ₹9.76 each. This strategic move aims to enhance AHCL's vertical integration and secure the supply of high-quality pharmaceutical intermediates. Apiqo Organics reported a turnover of ₹3,887.41 Lakh as of October 31, 2025.
Key Highlights
Acquisition of 67.48% shareholding in Apiqo Organics Private Limited
Acquisition cost of ₹5,40,06,960
55,33,500 equity shares acquired at ₹9.76 per share
Apiqo Organics turnover of ₹3,887.41 Lakh as of 31.10.2025
Expected completion of acquisition within 3 months
👀 What to Watch
This acquisition is expected to strengthen AHCL's position in the pharmaceutical industry. Investors should monitor the integration of Apiqo Organics and its impact on AHCL's future earnings.
